Companies: 10,795·Total market cap: $144.5T
CinCor Pharma, Inc.

CinCor Pharma, Inc.

CINCNASDAQHealthcare
$29.06
+$0.00(+0.00%)
Market Cap$1.3B
P/E Ratio
52W High$43.15
52W Low$10.53

CinCor Pharma, Inc. (CINC) PE Ratio — Current & Historical Data

Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.

cinc · pe ratio · data through Dec 31, 2021

Core PE Ratio Metrics

Trailing 12 months · TTM

The price-to-earnings (P/E) ratio for CinCor Pharma, Inc. (CINC) measures how much investors pay for each dollar of the company's trailing earnings. CINC's current PE ratio of N/A is calculated by dividing its stock price of $29.06 by its TTM earnings per share of -$1.42.

N/A
P/E Ratio (TTM)N/A — Company is not profitable (TTM)

Source: FMP · /ratios-ttm · /analyst-estimates · 2021-12-31

Forward P/E
N/A
EPS (TTM)
-$1.42
TTM · diluted EPS
PEG Ratio
0.23
Below 1.0 · Growth adjusted
Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · CinCor Pharma, Inc. SEC 10-K & 10-Q filings · US GAAPUpdated: 2026-06-09

PE Ratio History

2019 – 2021 · Annual
PE Ratio (TTM)
EPS (Annual)

▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)

PE Ratio vs Peers

Biotechnology · 6 peers · Annual PE
CompanyMarket CapPE (Annual)vs AvgEPS (TTM)
CinCor Pharma, Inc.
CinCor Pharma, Inc.You
CINC
$1.3BN/A-$1.42
Albireo Pharma, Inc.
Albireo Pharma, Inc.
ALBO
$916MN/A-$7.87
CTI BioPharma Corp.
CTI BioPharma Corp.
CTIC
$1.2BN/A-$0.79
EQRx, Inc.
EQRx, Inc.
EQRX
$1.1B5.68x-10.5%$0.43
Ethzilla Corp.
Ethzilla Corp.
ETHZ
$56MN/A-$5517.71
Gracell Biotechnologies Inc.
Gracell Biotechnologies Inc.
GRCL
$198MN/A-$44.87
POINT Biopharma Global Inc.
POINT Biopharma Global Inc.
PNT
$1.3B7.02x+10.5%$1.04
Industry Average
2 peers with valid PE
6.35xbaseline

* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio

Annual PE Ratio History

Showing 3 of 3 years
Fiscal Year EndPE RatioEPS (TTM)YoY ChangePE vs Max
2021-12-31Latest
FY2021
$-1.42
2020-12-31
FY2020
$-0.95
2019-12-31
FY2019
$-0.21

▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API

About PE Ratio & Methodology

The price-to-earnings (P/E) ratio for CinCor Pharma, Inc. (CINC) measures how much investors pay for each dollar of the company's trailing earnings. CINC's current PE ratio of N/A is calculated by dividing its stock price of $29.06 by its TTM earnings per share of -$1.42.

PE Ratio = Stock Price ÷ EPS (TTM)
= $29.06 ÷ -$1.42 = N/A
TTMTrailing Twelve Months — sum of the most recent 4 quarterly EPS figures
Forward PEStock price ÷ analyst consensus EPS estimate for the next fiscal year
PEGPE ÷ earnings growth rate — values below 1.0 suggest growth may justify the premium
Figures tie to SEC 10-K/10-Q and FMP ratio endpoints where noted.

Frequently asked questions

CINC pe ratio · 6 questions

CINC's current PE ratio is N/A as of 2026-06-09, based on a stock price of $29.06 and TTM EPS of -$1.42. Data sourced from Financial Modeling Prep via CINC's SEC 10-K and 10-Q filings.

CINC PE ratioWhat is CINC PE ratioCurrent PE ratio of CINCCINC PE ratio today

Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · CinCor Pharma, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09